About us
Uniogen is a Finnish frontrunner in diagnostics solutions and instrumentation for life sciences. The company specializes in developing and manufacturing innovative diagnostic tests, assay components, and instruments. Trusted by customers worldwide, we also provide assay development and contract manufacturing services for the IVD and life sciences industries.
At Uniogen, we are committed to delivering comprehensive solutions tailored to the evolving needs of diagnostics and life sciences. Our expertise spans early cancer detection, molecular diagnostics, immunoassays, and advanced instrumentation. We are a trusted provider of comprehensive CDMO and OEM services for assay development and contract manufacturing across all these areas.
With 20 years of experience in assay development and the diagnostics market, we bring deep scientific expertise and technical excellence to every solution we create. Our highly skilled team of scientists ensures the development of high-quality, reliable, and efficient products and services, as was demonstrated by our latest excellent NPS (Net Promoter Score) of 71. Through cutting-edge technology, research and strategic collaborations, we are dedicated to driving innovation and improving patient outcomes worldwide.
Uniogen was established when Kaivogen, a specialist in cancer diagnostics, immunoassays and antibody testing, Labrox, an innovator of high-end laboratory instruments and diagnostic readers, and Abacus Diagnostica, a frontrunner in rapid PCR and molecular testing joined forces in 2022. The company is headquartered in Turku, Finland, and employs around 75 life science professionals. Uniogen products are sold globally through our valued partners.
“The large upcoming product family for early cancer detection, under development, will open great growth opportunities for us in the global diagnostics market.
Together, we have combined immunoassay, PCR, and instrumentation expertise enabling us to develop new innovative diagnostics products by addressing unmet customer needs.
Uniogen products currently under development include e.g. high-performance assay for early detection of ovarian cancer, and innovative solutions for point-of-care testing.”
– Ilari Antila, CEO
Uniogen is proud to have a track record of established, long-term partnerships with CDMO services for corporate US and European IVD corporate customers.
Partner with us to become the latest addition to our valued customer base. For further information on Uniogen services, please contact us here.